| Patents for C07K 7 - Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof (42,273) |
|---|
| 09/16/2003 | CA2215695C .beta.-sheet mimetics and use thereof as protease inhibitors |
| 09/16/2003 | CA2172493C Use of angiotensin iii and analogs thereof in tissue repair |
| 09/16/2003 | CA2090860C Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures |
| 09/16/2003 | CA2054590C Novel cyclosporins |
| 09/12/2003 | WO2003074558A2 Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, and treatments and animal models produced therefrom |
| 09/12/2003 | WO2003074546A2 Streptavidin-binding peptide |
| 09/12/2003 | WO2003074005A2 Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
| 09/12/2003 | WO2003037268A3 Hepta-, octa- and nonapeptides having antiangiogenic activity |
| 09/12/2003 | WO2002102835A3 Novel antimicrobial compounds |
| 09/12/2003 | WO2002002488A9 Methods and compounds for modulating nuclear receptor coactivator binding |
| 09/12/2003 | WO2001095785A3 Modulation of immune response and methods based thereon |
| 09/12/2003 | CA2666005A1 Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
| 09/12/2003 | CA2478636A1 Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, and treatments and animal models produced therefrom |
| 09/12/2003 | CA2477836A1 Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
| 09/12/2003 | CA2476182A1 Conjugates of therapeutic or cytotoxic agents and biologically active peptides |
| 09/11/2003 | WO2003074551A2 Conjugates of therapeutic or cytotoxic agents and biologically active peptides |
| 09/11/2003 | US20030171539 Synthetic oligopeptide heparin-neutralizing agents including basic amino acids and a N-heterocyclic end group; low turbidity; side effects reduction; in vitro diagnosis; calculate the blood clotting time; assaying clotting cascade |
| 09/11/2003 | US20030171289 Peptides blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
| 09/11/2003 | US20030171280 Compositions and methods for modulation of immune responses |
| 09/11/2003 | US20030171278 Novel compounds which bind to the human erbB2 gene product (ErbB2, also known as HER2, or c-ErbB-2). In particular aspects, the invention provides for the treatment of disorders characterized by the overexpression of ErbB2 utilizing the |
| 09/11/2003 | US20030171274 Antimicrobial proteins |
| 09/11/2003 | US20030171266 Frameshift mutants of beta-amyloid precursor protein and ubiquitin-b and their use |
| 09/11/2003 | US20030170894 Tryptophan containing low molecular weight polylysine, for use in receptor-mediated and nonreceptor-mediated gene delivery, both in vivo and in vitro |
| 09/11/2003 | US20030170792 MAGE-3 peptides presented by HLA class ll molecules |
| 09/11/2003 | US20030170766 Methods and compositions for inhibiting farnesyl transferase enzyme |
| 09/11/2003 | US20030170735 Introducing suspension of mammalian cells to combinatorial peptide library comprising multiple beads with attached synthetic compounds, incubating, identifying bead with growing cells, isolating, determining structure of compound |
| 09/11/2003 | US20030170658 Genetic engineered retroviruses; detecting antigen, antibody complex; medical diagnosis |
| 09/11/2003 | US20030170620 Gene controlling androgen |
| 09/10/2003 | EP1341819A2 Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic medicament |
| 09/10/2003 | EP1341548A2 METHODS FOR IDENTIFYING TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY $g(b)-AMYLOID PEPTIDES |
| 09/10/2003 | EP1054689B1 Strategically modified hepatitis b core proteins and their derivatives |
| 09/10/2003 | EP0760678B1 Quantification of individual protein kinase activity |
| 09/10/2003 | CN1441811A Anti-body capable to selectively detect prion PrPsc isoforms |
| 09/10/2003 | CN1441806A Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties |
| 09/10/2003 | CN1441606A Method for establishing mobile station connection in cellular telecommunications system |
| 09/10/2003 | CN1120846C Somatotropin releasing peptide and its application |
| 09/10/2003 | CN1120845C Process for separating and extracting nisin from fermented liquid |
| 09/09/2003 | US6617424 Undecapeptides containing cysteinesulfinic and cysteinesulfenic acid |
| 09/09/2003 | US6617309 Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease |
| 09/09/2003 | US6617307 Useful for treatment of fractures, as a filler in deficient sites of bone, for inhibition of decrease in bone substance related to osteoporosis and periodontic diseases |
| 09/09/2003 | US6617110 Cultured cell comprising a nucleic acid sequence, encoding the protein, that hybridizes to a polynucleotide of given sequence; use to determine if drug is cytotoxic; can use as anticarcinogenic agent |
| 09/04/2003 | WO2003073097A2 Methods for isolating ligands e.g. t cell epitopes |
| 09/04/2003 | WO2003073066A2 Reagents and methods for assaying bacillus anthracis lethal factor protease |
| 09/04/2003 | WO2003072754A2 Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use |
| 09/04/2003 | WO2003072600A2 Methods of screening molecular libraries for active molecules that restore the function of target proteins and peptides that restore the function of mutant p53 |
| 09/04/2003 | WO2003072599A2 Novel chemokine binding peptides capable of modulating the biological activity of chemokines |
| 09/04/2003 | WO2003072597A1 Intermediates and methods for making heptapeptide oxytocin analogues |
| 09/04/2003 | WO2003072593A2 Bone targeting peptides |
| 09/04/2003 | WO2003072556A1 Glutaminyl based dpiv inhibitors |
| 09/04/2003 | WO2003072542A2 Interfacial biomaterials |
| 09/04/2003 | WO2003072061A2 Methods and compositions for treating gastrointestinal toxicity induced by cytoablative therapy |
| 09/04/2003 | WO2003072059A2 Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth |
| 09/04/2003 | WO2003072039A2 Cosmetic formulations containing l-arginine oligomers |
| 09/04/2003 | WO2003072034A2 Cyclic peptides and analogs useful to treat allergies |
| 09/04/2003 | WO2003062267A3 Enzyme substrates for the determination of activity of staphylococcus sp. extracellular protease |
| 09/04/2003 | WO2003057723A3 Fluorogenic protease substrates doubly labelled with rhodamine moieties |
| 09/04/2003 | WO2003039438A3 Pna-conjugates for treating chronic myeloid leukaemia (cml) |
| 09/04/2003 | WO2003002593A3 Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis |
| 09/04/2003 | WO2002103016A3 Human tachykinin-related splice variants and compositions thereof |
| 09/04/2003 | WO2002083858A8 Methods to inhibit viral replication |
| 09/04/2003 | WO2002032932A3 Urotensin-ii agonists and antagonists |
| 09/04/2003 | WO2002020769A9 Human and mouse targeting peptides identified by phage display |
| 09/04/2003 | US20030167129 Antiinflammatory agents; detecting binding to cellular library; separation; calibration |
| 09/04/2003 | US20030166876 Method of treating cancer including administering a human chimeric antibody specific for the ganglioside GD3 |
| 09/04/2003 | US20030166853 Mucin peptide with immunoenhancing properties |
| 09/04/2003 | US20030166849 A peptide of at least 5 amino acids containing a unique portion of a semaphorin, and such peptide has a semaphorin binding specificity |
| 09/04/2003 | US20030166837 Isolated molecules which complex with HLA-Cw*16 molecules, and uses thereof |
| 09/04/2003 | US20030166832 Methods and compositions for impairing multiplication of HIV-1 |
| 09/04/2003 | US20030166580 Substituted amino carboxamides for the treatment of alzheimer's disease |
| 09/04/2003 | US20030166569 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 09/04/2003 | US20030166556 Immunoregulator |
| 09/04/2003 | US20030166549 Targeting peptides |
| 09/04/2003 | US20030166545 Compounds and use thereof to modify transport across cell membranes |
| 09/04/2003 | US20030166539 Compositions and methods of use for a bombesin peptide |
| 09/04/2003 | US20030166529 Polypeptides and their uses |
| 09/04/2003 | US20030166515 Cyclosporins for the treatment of immune disorders |
| 09/04/2003 | US20030166514 Pharmaceutical composition comprising (a) the cyclic peptide compound of Formula 1 or Formula 2 as antigrowth agents or anticancer agents |
| 09/04/2003 | US20030166505 Neo-tryptophan |
| 09/04/2003 | US20030166138 For modulating interleukin-4 receptor mediated germline epsilon transcription; for treatment of diseases associated with immunoglobulin production/accumulation |
| 09/04/2003 | US20030166033 Uses of synthetic peptides corresponding to telopeptide sequences of cross-linked type l collagen metabolites |
| 09/04/2003 | US20030166004 Comprises synthetic or genetically engineered peptide or polypeptide which comprises endothelial cell binding peptides (ECBP) for inhibit angiogenesis and related diseases such as cancer, arthritis and vision defects |
| 09/04/2003 | US20030166003 Structured peptide scaffold for displaying turn libraries on phage |
| 09/04/2003 | US20030165822 Binding molecules for human factor VIII and factor VIII-like proteins |
| 09/04/2003 | US20030165567 Administering polypeptide by injection; gene therapy |
| 09/04/2003 | US20030165503 Vaccine for the treatment of atherosclerosis |
| 09/04/2003 | US20030165432 Versatile hydrophilic dyes |
| 09/04/2003 | US20030165427 Tuftsin metallopeptide analogs and uses thereof |
| 09/04/2003 | CA2479812A1 Glutaminyl based dpiv inhibitors |
| 09/04/2003 | CA2477231A1 Methods and compositions for treating gastrointestinal toxicity induced by cytoablative therapy |
| 09/04/2003 | CA2476571A1 Method for isolating ligands |
| 09/04/2003 | CA2475953A1 Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth |
| 09/04/2003 | CA2467836A1 Interfacial biomaterials |
| 09/03/2003 | EP1340816A2 Quantitation of individual protein kinase activity |
| 09/03/2003 | EP1340768A2 LHRH analogues for the treatment of osteoporosis |
| 09/03/2003 | EP1340767A2 Polypeptide useful as biomaterial and process for producing the same |
| 09/03/2003 | EP1339837A2 Prolyl endoprotease from aspergillus niger |
| 09/03/2003 | EP1339746A2 Binding polypeptides for b lymphocyte stimulator protein (blys) |
| 09/03/2003 | CN1440422A Novel gonadotropin-releasing hormone, precursor peptides thereof and genes encoding the same |
| 09/03/2003 | CN1440420A Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases |
| 09/02/2003 | US6614831 Mounting arrangement for auxiliary burner or lance |